Blog
RSS FeedPosted by Michael Wonder on 26 Jul 2017
Institute for Clinical and Economic Review announces potential topics for review in 2018
26 July 2017 - Tentative list includes drugs for migraines, haemophilia, and cystic fibrosis. ...
Posted by Michael Wonder on 25 Jul 2017
Dr Steve Pearson on using health technology assessment to guide decision making
23 July 2017 - Health technology assessment is a tool that helps to objectively evaluate evidence, which levels the playing field ...
Posted by Michael Wonder on 17 Jul 2017
Institute for Clinical and Economic Review's final evidence report finds prices of anabolic agents for osteoporosis too high, not aligned with potential benefits over other treatments
17 July 2017 - Policy recommendations highlight need for prices to align with clinical benefit, clear guidelines to define highest ...
Posted by Michael Wonder on 13 Jul 2017
ICER releases draft evidence report reviewing olaparib, rucaparib, and niraparib for ovarian cancer
12 July 2017 - Public comment period now open until 9 August; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 20 Jun 2017
When cholesterol drugs cost $14,000, an insurance tug-of-war
19 June 2017 - Patients struggle to obtain PCSK9 inhibitors, a powerful class of drugs that lower bad cholesterol in difficult ...
Posted by Michael Wonder on 17 Jun 2017
Institute for Clinical and Economic Review report finds inadequate evidence to distinguish between anabolic therapies for osteoporosis
16 June 2017 - Cost-effectiveness analyses find prices too high to align with added benefit to patients. ...
Posted by Michael Wonder on 13 Jun 2017
Institute for Clinical and Economic Review’s “new evidence update” on PCKS9 inhibitors highlights lack of mortality benefit with evolocumab
13 June 2017 - Newly released clinical trial data show expected reductions in stroke and heart attack, but mortality benefit ...
Posted by Michael Wonder on 08 Jun 2017
Institute for Clinical and Economic Review's final report on treatments for atopic dermatitis provides policy recommendations to support appropriate patient access to dupilumab
8 June 2017 - Report analyses evidence on the comparative effectiveness of dupilumab, finds price well-aligned with added value for patients; ...
Posted by Michael Wonder on 07 Jun 2017
Converging on the value of value frameworks
6 June 2017 - The relentless increase in health care costs has been difficult to control and is widely believed to ...
Posted by Michael Wonder on 27 May 2017
Dr Steve Pearson outlines the importance of thresholds on determining value
23 May 2017 - Thresholds can be useful to focus the conversation around the value of treatments in healthcare even if ...
Posted by Michael Wonder on 22 May 2017
Another voice: Patients have a right to the treatments ordered by doctors
22 May 2017 - For too long, insurance-backed groups have been given enormous power to overrule doctors’ orders and make ...
Posted by Michael Wonder on 13 May 2017
Institute for Clinical and Economic Review releases revised evidence report on dupilumab and crisaborole for treatment of atopic dermatitis
12 May 2017 - Limitations noted on the evidence for crisaborole; analyses find stronger evidence for dupilumab and suggest its price ...
Posted by Michael Wonder on 11 May 2017
Institute for Clinical and Economic Review posts briefing paper on assessing the value of drugs for rare conditions
10 May 2017 - Report contains a technical brief on Spinraza and will inform discussions at ICER pricing summit on 31 ...
Posted by Michael Wonder on 08 May 2017
Institute for Clinical and Economic Review posts draft scoping document on treatments for tardive dyskinesia, including recently approved Ingrezza
8 May 2017 - Report expected to review evidence on deutetrabenazine (Austedo), tetrabenazine (Xenazine), and valbenazine (Ingrezza); scoping document will be ...
Posted by Michael Wonder on 04 May 2017
ICER releases draft evidence report on treatments for osteoporosis, including abaloparatide and romosozumab
3 May 2017 - Abaloparatide recently approved by FDA, romosozumab under FDA review; public comment and requests to give oral comment ...